| Not Yet Recruiting | Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: NCT07199413 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis NCT07348965 | Guangzhou University of Traditional Chinese Medicine | N/A |
| Recruiting | Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomening NCT07398599 | Second Affiliated Hospital of Nanchang University | N/A |
| Not Yet Recruiting | A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases NCT07177950 | Peking University Cancer Hospital & Institute | Phase 1 / Phase 2 |
| Recruiting | Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertini NCT06296745 | Guangzhou Medical University | Phase 2 |
| Recruiting | Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases NCT07098806 | Plus Therapeutics | Phase 1 |
| Not Yet Recruiting | AI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Lept NCT07005791 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Active Not Recruiting | Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With L NCT06984523 | NYU Langone Health | N/A |
| Recruiting | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal M NCT07092202 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 |
| Recruiting | Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis NCT06809517 | Guangzhou Medical University | Phase 1 / Phase 2 |
| Recruiting | Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Meta NCT06809530 | Guangzhou Medical University | Phase 1 / Phase 2 |
| Recruiting | Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bisp NCT06762080 | Guangzhou Medical University | Phase 1 / Phase 2 |
| Recruiting | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for th NCT06901817 | Shanghai Cancer Hospital, China | Phase 2 |
| Recruiting | Concurrent Azeliragon With Craniospinal Irradiation NCT06724926 | NYU Langone Health | Phase 1 |
| Recruiting | Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metasta NCT06643000 | Henan Cancer Hospital | N/A |
| Recruiting | Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC NCT06663306 | Shanghai Chest Hospital | Phase 1 |
| Not Yet Recruiting | Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EG NCT06441045 | Fujian Cancer Hospital | Phase 2 |
| Enrolling By Invitation | Retrospective Study on Leptomeningeal Metastasis of Solid Tumors NCT06705049 | Shanghai Zhongshan Hospital | — |
| Active Not Recruiting | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases NCT06282874 | Guangdong Association of Clinical Trials | Phase 4 |
| Recruiting | Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC NCT05805631 | Taipei Veterans General Hospital, Taiwan | Phase 2 |
| Active Not Recruiting | Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From NCT06462222 | Guangzhou Medical University | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lun NCT06431685 | Sichuan University | Phase 1 |
| Recruiting | Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation S NCT06304441 | Guangzhou Medical University | N/A |
| Recruiting | Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metast NCT06230055 | Fudan University | Phase 4 |
| Recruiting | Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease NCT05800275 | UNICANCER | Phase 2 |
| Recruiting | Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis NCT05746754 | University of Aarhus | N/A |
| Recruiting | Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir NCT06399926 | Xiangya Hospital of Central South University | — |
| Recruiting | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer NCT06058988 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Intrathecal Double Checkpoint Inhibition NCT05598853 | University of Zurich | Phase 1 |
| Terminated | A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide NCT05414123 | Biocept, Inc. | — |
| Withdrawn | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malig NCT04315246 | Y-mAbs Therapeutics | Phase 1 / Phase 2 |
| Unknown | Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis NCT05305885 | The First Hospital of Jilin University | N/A |
| Recruiting | CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease NCT05257967 | British Columbia Cancer Agency | N/A |
| Unknown | Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Ca NCT05385185 | Hebei Medical University | Phase 2 |
| Completed | Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation NCT05146219 | TYK Medicines, Inc | Phase 2 |
| Recruiting | Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis NCT06417710 | University of Zurich | — |
| Active Not Recruiting | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases NCT05034497 | Plus Therapeutics | Phase 1 |
| Unknown | Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis NCT04944069 | Second Affiliated Hospital of Nanchang University | N/A |
| Unknown | Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastas NCT04833205 | Hui Bu | Phase 2 |
| Unknown | A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTIST NCT04778800 | Henan Cancer Hospital | N/A |
| Terminated | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases NCT04729348 | Massachusetts General Hospital | Phase 2 |
| Recruiting | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease NCT04588545 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation NCT04233021 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Unknown | Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastas NCT04356118 | Hui Bu | Phase 4 |
| Unknown | Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis NCT04356222 | Hui Bu | Phase 4 |
| Completed | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease NCT04420598 | MedSIR | Phase 2 |
| Completed | Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis NCT07239102 | Beijing Tiantan Hospital | — |
| Active Not Recruiting | GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal NCT04192981 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metast NCT04148898 | Second Affiliated Hospital of Nanchang University | Phase 2 |
| Withdrawn | Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Me NCT03974204 | Centre Oscar Lambret | N/A |
| Completed | Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tum NCT03507244 | The First Hospital of Jilin University | Phase 1 / Phase 2 |
| Unknown | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer NCT04425681 | Second Affiliated Hospital of Nanchang University | Phase 2 |
| Completed | Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer NCT02948751 | Columbia University | — |
| Completed | Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid T NCT03082144 | The First Hospital of Jilin University | Phase 2 |
| Completed | Tomotherapy for Leptomeningeal Metastases NCT04178343 | Chinese Academy of Medical Sciences | N/A |
| Completed | Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM) NCT02071056 | Dartmouth-Hitchcock Medical Center | — |
| Unknown | A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Le NCT02803619 | Peking Union Medical College Hospital | — |
| Completed | Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis NCT01281696 | National Taiwan University Hospital | Phase 2 |